Luke T Nordquist MD

Oncology•Omaha, NE

Genitourinary Oncology, Hematologic Oncology

CEO and Medical Director, Urology Cancer Center and GU Research Network

Join to View Full Profile

7710 Mercy RdSte 122Omaha, NE 68124
Phone+1 402-393-3110
Fax+1 402-393-4499

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2001 - 2004
University of South Florida MorsaniResidency, Internal Medicine, 1998 - 2001
Creighton University School of MedicineClass of 1998

Certifications & Licensure

NE State Medical License 2003 - 2026
NY State Medical License 2000 - 2005
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2011-2013
QOPI Certification ASCO

Clinical Trials

A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer Start of enrollment: 2012 Dec 01
Terminated
Phase 2
A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Start of enrollment: 2011 Dec 01
Completed
Phase 2
Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis Start of enrollment: 2014 Mar 01
Completed
Phase 2
Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone. Start of enrollment: 2015 May 01
Completed
Phase 2
Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer Start of enrollment: 2015 Jul 01
Completed
Phase 1
Extension of SoluMatrix TM Abiraterone Acetate in Patients Who Completed Study Number CHL-AA-201 Start of enrollment: 2016 Sep 01
Completed
Phase 3
Phase 1 Trial of PAN-301-1 (SNS-301) in Cancer Patients Start of enrollment: 2016 Dec 01
Completed
Phase 1
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer Start of enrollment: 2018 Jun 19
RECRUITING
PHASE3
Roles: Contact
INTREPId (INTermediate Risk Erection PreservatIon Trial) Start of enrollment: 2020 Jun 01
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Health-related quality of life, pain, and symptomatic skeletal events with [Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer...
Karim Fizazi, Michael J Morris, Neal D Shore, Kim N Chi, Michael Crosby
The Lancet. Oncology. 2025-07-01
Organ and tumour dosimetry ofLu-rhPSMA-10.1, a novel PSMA-targeted therapy: results from a Phase I trial.
James Nagarajah, Hyun Kim, Luke Nordquist, Vikas Prasad, Nathaniel Scott
European Journal of Nuclear Medicine and Molecular Imaging. 2025-05-06
Intensifying Salvage Therapy in Prostate-specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy with Apalutamide, Salvage Radiation, and Docetaxel: The...
Tian Zhang, Lauren Howard, Bridget F Koontz, Scott T Tagawa, Himanshu Nagar
European Urology Oncology. 2025-04-01

Journal Articles

Phase 1 Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer
Mark T Fleming, Luke T Nordquist, William R Berry, Clinical Cancer Research

Press Mentions

First Patient Imaged in Phase III AMPLIFY Trial with 64Cu-SAR-bisPSMA PET/CTMay 29th, 2025
Clarity Completes First Stage of Prostate Cancer TrialMay 25th, 2023
Clarity's Theranostic Prostate Cancer Trial Advances to Cohort 2May 24th, 2023
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member